US sales in Q1 is estimated at USD 270-276 million from USD 285 million (QoQ), due to pricing pressure in drugs such as Valcyte & Vidaza generic. Also, there may be some pressure in US due to market share loss in Sumatriptan auto-injector and Dacogen generic.
first published: Jul 25, 2016 12:00 pm
A collection of the most-viewed Moneycontrol videos.
Live: Nifty extends gain for the third day, up nearly 2% this week | Closing Bell | 4K
From renewables to AI and SMEs: Madhusudan Kela on where he senses opportunity now
Will The Pre-Diwali Nifty Rally Rage On Amid Weak Global Cues? RIL Q2 in Focus | Opening Bell Live
Infosys Q2 Earnings Live | Decoding Infosys Q2 Earnings | Earnings Express
